Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Anxiety Disorders 2 Weight Loss 1 Recurrence 1 Lung Neoplasms 1 Glioma 1 Fatigue 1 Depression 1 Colorectal Adenocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Cachexia 1 Brain Neoplasms 1 Advanced Cancer 1 Adenocarcinoma of Lung 1

Interventions

Surveys and Questionnaires 7 Standard of Care 5 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Interviews as Topic 4 Paclitaxel 3 olaparib 2 Vorinostat 2 Olanzapine 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Dasatinib 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olanzapine-fluoxetine combination 1 nimotuzumab 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × Fluoxetine × Clear all

NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡